Organogenesis stock: Organogenesis published PREPARE results. November 5 tests Organogenesis stock

Published on 10/23/2026 at 02:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PREPARE showed a 12-week benefit October 12, 2026. Organogenesis stock faces November 5, 2026 results after USD 42.80 million second-quarter revenue.

Clinical evidence meets earnings calendar

Organogenesis reported a 12-week PREPARE benefit on October 12, 2026.
Second-quarter net product revenue was USD 42.80 million versus USD 100.80 million a year earlier.
Third-quarter 2026 results are scheduled for November 5, 2026.

ORGO, US68621F1021, Illustration mit AI erstellt.

Organogenesis Holdings (ISIN US68621F1021) said on October 12, 2026 that published PREPARE trial results showed a clinical benefit for PuraPly AM in hard-to-heal diabetic foot ulcers, according to GlobeNewswire. The randomized study reached its primary endpoint and reported statistically significant improvement in wound closure at 12 weeks.

PREPARE adds clinical evidence

The publication gives Organogenesis a clinical data point for its advanced wound care portfolio. The company said PuraPly AM plus standard care was evaluated against standard care alone in hard-to-heal diabetic foot ulcers, with the 12-week result supporting the product's use in a difficult chronic-wound population, according to GlobeNewswire.

Three dated developments

On August 6, 2026, Organogenesis reported second-quarter net product revenue of USD 42.80 million, compared with USD 100.80 million in the year-earlier quarter, according to Bullscope. On October 12, 2026, the PREPARE publication supplied the latest clinical update. On the same date, the company set November 5, 2026 for its third-quarter financial results.

What does the trial mean for sales?

The trial result strengthens the evidence story, but the second-quarter revenue comparison shows the commercial pressure that the next report must address. Revenue of USD 42.80 million was USD 58.00 million below the year-earlier figure of USD 100.80 million, a decline of 57.54 percent.

November 5 brings results

Organogenesis will report third-quarter fiscal 2026 results after the market closes on November 5, 2026, and management will host a conference call at 5:00 p.m. ET, according to GlobeNewswire. That date is the next scheduled test of whether the clinical evidence can be matched by operating performance.

Market value and business model

Organogenesis had a market capitalization of USD 132.5 million on October 22, 2026. The Nasdaq-listed company develops and sells regenerative medicine products for advanced wound care, surgical and sports medicine applications.

The further course of trading is shown by the continuously updated real-time quote of Organogenesis stock.